A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer and Expansion Phase in Subjects with Advanced EGFR mutated Non-Small Cell Lung Cancer who are resistant to EGFR tyrosine kinase inhibitors
Latest Information Update: 12 Mar 2024
Price :
$35 *
At a glance
- Drugs Brigatinib (Primary) ; Cetuximab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2024 Status changed from recruiting to discontinued.
- 31 Aug 2021 New trial record